HomeDNLI • NASDAQ
Denali Therapeutics Inc
add
In the news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 35.48M | 42.23% |
Net income | -126.90M | -18.39% |
Net profit margin | — | — |
Earnings per share | -0.74 | -17.46% |
EBITDA | -133.57M | -10.46% |
Effective tax rate | — | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 848.20M | 1.39% |
Total assets | 1.06B | -27.40% |
Total liabilities | 129.42M | -4.50% |
Total equity | 926.20M | — |
Shares outstanding | 146.66M | — |
Price to book | 2.77 | — |
Return on assets | -30.93% | — |
Return on capital | -33.59% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | -126.90M | -18.39% |
Cash from operations | -107.30M | -81.43% |
Cash from investing | 57.83M | -38.25% |
Cash from financing | -778.00K | 95.81% |
Net change in cash | -50.24M | -414.87% |
Free cash flow | -54.15M | -30.46% |
Previous close
$17.48
Day range
$16.97 - $17.60
Year range
$10.57 - $26.18
Market cap
2.51B USD
Avg Volume
1.55M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
Founded
2013
Headquarters
Website
Employees
517
